|
1
|
Stang A, Parkin DM, Ferlay J and Jöckel
KH: International uveal melanoma incidence trends in view of a
decreasing proportion of morphological verification. Int J Cancer.
114:114–123. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh AD and Topham A: Incidence of uveal
melanoma in the United States: 1973–1997. Ophthalmology.
110:956–961. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Egan KM, Seddon JM, Glynn RJ, Gragoudas ES
and Albert DM: Epidemiologic aspects of uveal melanoma. Surv
Ophthalmol. 32:239–251. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bedikian AY, Legha SS, Mavligit G,
Carrasco CH, Khorana S, Plager C, Papadopoulos N and Benjamin RS:
Treatment of uveal melanoma metastatic to the liver: A review of
the M.D. Anderson Cancer Center experience and prognostic factors.
Cancer. 76:1665–1670. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clarke C, Madden SF, Doolan P, Aherne ST,
Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown
J, et al: Correlating transcriptional networks to breast cancer
survival: A large-scale coexpression analysis. Carcinogenesis.
34:2300–2308. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wan Q, Tang J, Han Y and Wang D:
Co-expression modules construction by WGCNA and identify potential
prognostic markers of uveal melanoma. Exp Eye Res. 166:13–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi Z, Derow CK and Zhang B: Co-expression
module analysis reveals biological processes, genomic gain, and
regulatory mechanisms associated with breast cancer progression.
BMC Syst Biol. 4:742010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Udyavar AR, Hoeksema MD, Clark JE, Zou Y,
Tang Z, Li Z, Li M, Chen H, Statnikov A, Shyr Y, et al:
Co-expression network analysis identifies Spleen Tyrosine Kinase
(SYK) as a candidate oncogenic driver in a subset of small-cell
lung cancer. BMC Syst Biol. 7 Suppl 5:S12013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ihaka R and Gentleman R: R: A language for
data analysis and graphics. J Comput Graph Stat. 5:299–314. 1996.
View Article : Google Scholar
|
|
11
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. Nat
Genet. 25:25–29. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanehisa M, Goto S, Kawashima S, Okuno Y
and Hattori M: The KEGG resource for deciphering the genome.
Nucleic Acids Res. 32:(Database Issue). D277–D280. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gong J, Cao J, Liu G and Huo JR: Function
and mechanism of F-box proteins in gastric cancer (Review). Int J
Oncol. 47:43–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Testa U: Proteasome inhibitors in cancer
therapy. Curr Drug Targets. 10:968–981. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sane S and Rezvani K: Essential roles of
E3 ubiquitin ligases in p53 regulation. Int J Mol Sci. 18:E4422017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weathington NM and Mallampalli RK:
Emerging therapies targeting the ubiquitin proteasome system in
cancer. J Clin Invest. 124:6–12. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang
Z and Wei W: Targeting the ubiquitin pathway for cancer treatment.
Biochim Biophys Acta. 1855:50–60. 2015.PubMed/NCBI
|
|
20
|
Gragoudas ES, Egan KM, Seddon JM, Glynn
RJ, Walsh SM, Finn SM, Munzenrider JE and Spar MD: Survival of
patents with metastases from uveal melanoma. Ophthalmology.
98:383–390. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harbour JW, Onken MD, Roberson ED, Duan S,
Cao L, Worley LA, Council ML, Matatall KA, Helms C and Bowcock AM:
Frequent mutation of BAP1 in metastasizing uveal melanomas.
Science. 330:1410–1413. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Woodman SE: Metastatic uveal melanoma:
Biology and emerging treatments. Cancer J. 18:148–152. 2012.
View Article : Google Scholar : PubMed/NCBI
|
